H.C. Wainwright analyst Swayampakula Ramakanth downgraded Elevation Oncology (ELEV) to Neutral from Buy with a 36c price target down from $1.0, after the company entered into a definitive merger agreement with Concentra Biosciences that includes a proposal to be acquired for a purchase price of 36c per share in cash.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology downgraded to Hold from Buy at TD Cowen
- Elevation Oncology downgraded to Market Perform from Outperform at William Blair
- Elevation Oncology Merges with Concentra Biosciences
- Elevation enters into agreement to be acquired by Concentra for 36c per share
- Elevation Oncology: Hold Rating Amid Strategic Uncertainty and Financial Constraints